Menu
INVESTOR RELATIONS
IR CONTACT
ir@spectracure.com
SUBSCRIBE
FINANCIAL REPORTS
PRESS RELEASES
FINANCIAL CALENDAR
SpectraCure provides recurring financial information according to the following plan. The company’s financial year is 1 January – 31 December.
Annual report for 2021
2022-04-20
Interim report – Q1 2022
2022-05-12
Half-yearly report 2022
2022-08-26
Interim report – Q3 2022
2022-11-17
Year-end Report, 2022
2023-02-22
Annual report, 2022
2023-04-20
Interim report – Q1 2023
2023-05-16
Annual general meeting 2023
2023-05-16
Half-yearly report 2022
2022-08-17
Interim report – Q3 2022
2022-11-16
10 LARGEST OWNERS
List of owners as of December 30, 2022.
Source: euroclear
Largest owner
Masoud Khayyami
Buzz AB
Cardeon AB
Nordnet Pensionsförsäkring AB
SEB LIFESL
Swedbank Försäkring AB
Futur Pension Försäkringsaktebolag
MTT Capital AB*
Holding AB Knut Hansson
Total, 10 largest owners
Other owners (Approx 16 570)
Total
Stocks
9 721 510
4 847 177
2 748 794
2 024 700
1 830 356
1 300 000
1 296 428
1 165 600
1 048 493
577 500
25 983 058
71 148 550
97 131 608
%
10,01%
4,99%
2,83%
2,08%
1,88%
1,34%
1,33%
1,20%
1,08%
0,59%
26,75%
73,25%
100,00%
THE SHARE
SpectraCure’s share is listed on the Nasdaq First North Growth Market under the short name SPEC and is traded via banks and stockbrokers. SpectraCure is a record company and its shares are registered in electronic form with Euroclear Sweden AB, where its share register is also kept. All shares are of the same type, have an equal right to a share in the Company’s assets and profits and have the same voting value. All shares are issued and fully paid up.
Shares AK
Number of shares: 97,131,608
ISIN: SE0007158118
The company does not currently have any outstanding warrants.
CERTIFIED ADVISER
First North provides infrastructure for trading and distributing share information. In order to be quoted on First North, a company must appoint a Certified Adviser who pilots the company through the application process and ensures that the company lives up to and continuously complies with the acquis. The Certified Adviser ensures that the company meets the entry requirements and the ongoing obligations associated with the company’s shares are approved for trading on First North. In addition, the Certified Adviser continually monitors the company’s compliance and reports immediately to the exchange if any rule is breached.
G & W Fondkommission is Certified Adviser for SpectraCure AB.
For more information about G & W fondkommission See http://www.gwkapital.se/
PROSPECTUS
SpectraCure utvecklar ett behandlingsystem för eliminering av inre solida cancertumörer. Vi fokuserar initialt på återfallscancer i prostata, med en förhoppning att i framtiden även kunna behandla andra cancerformer som primär prostatacancer. Metoden bygger ett egenutvecklat och patenterat behandlingsystem – en laserenhet som utför PDT-behandling och behandlar själva prostatan i kombination med en patenterad dosplaneringsplattform IDOSE®. Metoden gör det möjligt att styra laserljusdosen så att tumören exponeras för en optimal dos för att uppnå tillräcklig behandlingseffekt. Behandlingsystemet har potential att göra interstitiell PDT-behandling noggrann, exakt och säker för varje patient.